Han S B, Kang K R, Huh D H, Lee H C, Kim J H, Kang J H, Ma S H
Department of Pediatrics,College of Medicine,The Catholic University of Korea,Seoul,Republic of Korea.
Vaccine Bio Research Institute,College of Medicine,The Catholic University of Korea,Seoul,Republic of Korea.
Epidemiol Infect. 2015 Jun;143(8):1643-50. doi: 10.1017/S0950268814002441. Epub 2014 Sep 19.
We conducted a cross-sectional seroepidemiological study in 2012-2013 to determine the seroprevalence of varicella-zoster virus (VZV) in adolescents and adults living in Korea, where varicella vaccination has been recommended universally at age 12-15 months since 2005. Residual serum samples were collected from 1196 healthy adults and adolescents aged ⩾10 years between November 2012 and March 2013. The fluorescent antibody to membrane antigen (FAMA) test and enzyme-linked immunosorbent assay (ELISA) were performed to determine the seroprevalence of VZV. The seroprevalences of VZV were compared between six age groups: 10-19, 20-29, 30-39, 40-49, 50-59, and ⩾60 years. The seroprevalence of VZV in the entire study cohort was 99·1% according to the FAMA test and 93·1% as determined by ELISA. The seroprevalences of the six age groups were as follows: 96·0%, 99·5%, 99·5%, 99·5%, 100%, and 100%, respectively, by the FAMA test, and 83·3%, 93·0%, 93·0%, 97·5%, 94·5%, and 97·5%, respectively, by ELISA. Seroprevalence increased significantly with age (P < 0·001); moreover, the seroprevalence in subjects aged 10-19 years was significantly lower than in other age groups (P < 0·001), as measured by both the FAMA test and ELISA. Thus, strategies to increase protective immunity against VZV in teenagers are necessary.
2012年至2013年，我们开展了一项横断面血清流行病学研究，以确定韩国青少年和成年人中水痘-带状疱疹病毒（VZV）的血清流行率。自2005年起，韩国建议在12至15个月龄时普遍接种水痘疫苗。2012年11月至2013年3月期间，从1196名年龄≥10岁的健康成年人及青少年中收集了剩余血清样本。采用膜抗原荧光抗体（FAMA）试验和酶联免疫吸附测定（ELISA）来确定VZV的血清流行率。比较了六个年龄组（10至19岁、20至29岁、30至39岁、40至49岁、50至59岁及≥60岁）的VZV血清流行率。根据FAMA试验，整个研究队列中VZV的血清流行率为99.1%，ELISA测定结果为93.1%。六个年龄组的血清流行率如下：FAMA试验分别为96.0%、99.5%、99.5%、99.5%、100%和100%，ELISA分别为83.3%、93.0%、93.0%、97.5%、94.5%和97.5%。血清流行率随年龄显著增加（P<0.001）；此外，通过FAMA试验和ELISA测定，10至19岁受试者的血清流行率显著低于其他年龄组（P<0.001）。因此，有必要采取策略提高青少年对VZV的保护性免疫力。
